Results 271 to 280 of about 1,384,561 (311)

Benefit-Risk Assessment of Bevacizumab in the Treatment of Breast Cancer

Drug Safety, 2012
An evaluation of the benefit-versus-risk of bevacizumab in the treatment of advanced breast cancer is timely and relevant. Recently, the US FDA has withdrawn the approval of bevacizumab as a therapeutic option for the treatment of advanced breast cancer, generating controversy in the scientific community. Although the pivotal study (Eastern Cooperative
Dienstmann, Rodrigo, Ades Moraes, Felipe, Metzger-Filho, Otto, Saini, Kamal   +3 more
openaire   +3 more sources

Benefit-Risk Assessment of Tegaserod in Irritable Bowel Syndrome

Drug Safety, 2004
Tegaserod is a new partial agonist of serotonin 5-HT4 receptors specifically developed for the treatment of nondiarrhoeal forms of irritable bowel syndrome (IBS). Among its various effects is the stimulation of the peristaltic reflex with its promotility action appearing to affect the whole length of the gastrointestinal tract.
Lea, Richard, Whorwell, Peter J.; id_orcid 0000-0002-5220-8474   +1 more
openaire   +3 more sources

A Bayesian Approach for Benefit-Risk Assessment

Statistics in Biopharmaceutical Research, 2014
An important aspect of the drug evaluation process is to have an integrated benefit-risk assessment to determine, using some quantitative measures, whether the benefit outweighs the risk for the target population. Chuang-Stein et al. proposed a five-category random variable along with three global measures of benefit-risk assessment.
Yueqin Zhao, Jyoti Zalkikar, Ram C. Tiwari, Lisa M. LaVange   +3 more
openaire   +1 more source

A Benefit-Risk Assessment of Extended-Release Oxybutynin

Drug Safety, 2002
Oxybutynin is a muscarinic receptor antagonist, which has been available for a number of years in its original immediate-release (IR) formulation. While oxybutynin IR has proven effective for the treatment of overactive bladder, its extended use can be limited by adverse effects, particularly dry mouth.
openaire   +2 more sources

Benefit-risk assessment of acne therapies

The Lancet, 1997
N, Bénéton, H, Bocquet, A, Cosnes, J, Revuz, J C, Roujeau   +4 more
openaire   +3 more sources

Benefit-Risk Assessment of Irinotecan in Advanced Colorectal Cancer

Drug Safety, 2005
Irinotecan exerts its cytotoxic activity through inhibition of the nuclear enzyme topoisomerase I. It has been approved in most countries worldwide for treatment of patients with advanced colorectal cancer (CRC). Activity is seen in previously untreated patients and in patients refractory to fluorouracil treatment, whether it is given alone or in ...
openaire   +2 more sources

Risk-benefit in food safety and nutrition – Outcome of the 2019 Parma Summer School

Food Research International, 2021
Hans Verhagen, Ricardo Assunção, Francesca Cavaliere   +2 more
exaly  

[Benefit-risk assessment of vaccination strategies].

Medecine sciences : M/S, 2007
This article summarises the various stages of the risk/benefit assessment of vaccination strategies. Establishing the awaited effectiveness of a vaccination strategy supposes to have an epidemiologic description of the disease to be prevented. The effectiveness of the vaccine strategy will be thus expressed in numbers of cases, hospitalizations or ...
Thomas, Hanslik, Pierre Yves, Boëlle
openaire   +1 more source

Benefit-risk assessment—safety perspective

Abstract Benefit-risk assessment is a continuous process, using a variety of sources of information. The concepts that apply for the evaluation of a new safety signal are described and the content of the benefit-risk evaluation report provided.
Phil Ambery, Adrian Kilcoyne, Daniel O’Connor   +2 more
openaire   +1 more source

Benefit‐risk assessment: to quantify or not to quantify, that is the question

Pharmacoepidemiology and Drug Safety, 2011
Zhong, Yuan, Bennett, Levitan, Jesse A, Berlin   +2 more
openaire   +2 more sources